Affinium Pharmaceuticals, a biopharmaceutical company with U.S. offices in Austin, TX and focused on the development of novel anti-infective medicines, announced the started of a Phase 1 intravenous clinical trial of their new antibiotic pro-drug AFN-1720.
AFN-1720’s parent molecule is AFN-1252, which demonstrated an excellent efficiency, safety and tolerability in acute bacterial skin and skin structure infections (ABSSSI) in 2012 oral Phase 2a clinical trial. AFN-1252 inhibits bacterial fatty acid synthesis of Staphylococcus aureus, the common bacterial pathogen in human, including MRSA and vancomycin-intermediate S. aureus (VISA).
The new molecule AFN-1720 has unique, staphylococcal specific spectrum and is expected to protect the human gut microbiome with minimal side effects, such as antibiotic-induced diarrhea or C. difficile overgrowth.
Affinium also announced the closing of a follow-on funding with its current investors which supports the continued development of AFN-1720.
They are now set to present recently generated data at several medical conferences and business meetings: the closest meeting is “Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC)” held on September 10-13 at Denver, CO.
Their study appeared in recent scientific publications such as Journal of Chemotherapy, Antimicrobial Agents & Chemotherapy, Clinical Investigation and Pharmaceutical Sciences.
For more information, visit the website of Affinium Pharmaceuticals: http://www.afnm.com